Akadeum Life Sciences

By A2Hub Editorial. Published 2026-04-22. Last updated: 2026-04-22.

At a glance

• Founded: 2014
• HQ: Ann Arbor, Michigan
• Flagship technology: Buoyancy-activated cell sorting (BACS) using microbubbles
• Flagship product: Alerion cell separation system, launched 2023
• Funding raised: $20M+ closed in June 2025, on top of earlier rounds
• Customers: Research institutions, biopharma, and clinical translational researchers using BACS-enabled workflows
• Status: Private, commercial-stage
• Website: akadeum.com

The pitch in one line

Akadeum Life Sciences invented a new way to sort cells. The Ann Arbor team's microbubble-based buoyancy-activated cell sorting technology (BACS) lets researchers separate target cells from complex samples by floating them to the top of a tube, which is faster, gentler, and more scalable than the magnetic and flow-based methods that have dominated cell sorting for decades.

Founding story: a different kind of cell separation

Akadeum Life Sciences was founded in 2014 in Ann Arbor with a thesis that ran against the grain of the cell separation industry. For decades, the dominant cell sorting technologies have been magnetic activated cell sorting (MACS) and fluorescence activated cell sorting (FACS). MACS uses magnetic beads attached to antibodies to pull target cells out of suspension; FACS uses high-throughput flow cytometers to gate cells one at a time. Both work. Both have limitations. MACS leaves magnetic beads on the cells, which can interfere with downstream applications. FACS is slow per cell, requires expensive instrumentation, and stresses the cells under the optics-and-pressure regime of the cytometer.

Akadeum's founding team bet on a third option. Instead of magnetics or optics, use buoyancy. Attach gas-filled microbubbles to antibodies, conjugate the antibodies to target cells, and let the resulting bubble-cell complexes float to the top of the sample tube. The non-target cells stay in suspension at the bottom. The target cells (with their attached microbubbles) are separated by gravity in minutes. The technology is gentler than MACS or FACS, scales to large sample volumes more easily, and does not leave the same downstream interference.

That technology, branded buoyancy-activated cell sorting (BACS), is the foundation of Akadeum's product line. The company has spent the years since founding turning the BACS principle into commercial products, building distribution into research labs, and most recently launching the Alerion automated cell separation system.

What they build

Akadeum's product set spans:

BACS reagents. Microbubble reagents conjugated to antibodies for specific cell separation applications: T cell isolation, B cell isolation, depletion of specific cell populations, and a growing catalog of validated workflows.

Alerion cell separation system. Launched in 2023, Alerion is an automated benchtop instrument that runs BACS workflows with minimal user intervention. The instrument is the company's bet on graduating BACS from a manual lab-bench workflow into a routine automated process that hospital labs and biopharma manufacturing can adopt.

Custom and translational services. Bespoke development for biopharma and clinical translational customers building cell-based therapies and diagnostics that need sorting workflows tailored to their specific cell types.

The customer base spans academic and government research labs (the early-adopter market for new cell separation technology), biopharma R&D (where BACS workflows feed into therapeutic development), and translational and clinical labs (where BACS is increasingly used for cell-based therapy production).

Funding history

Akadeum closed a $20M+ financing in June 2025, the most recent of a series of rounds across the company's history. Total funding to date is meaningful but not at the unicorn-style scale of some life sciences peers; the company has been deliberate about capital efficiency, which fits the operating profile of a tools-and-reagents business.

The 2025 round funds continued commercial scale-up of the Alerion system, expansion of the reagent catalog, and the broader commercial team needed to grow customer adoption beyond the early-adopter research base.

Ann Arbor footprint

Akadeum operates from Ann Arbor and represents one of the smaller but more technically distinctive medtech employers in the city. The team spans research and development (with significant biology and chemistry talent), engineering (instrumentation, fluidics, software), and the commercial bench needed to sell into research and biopharma customers. Headcount is in the dozens, with the Ann Arbor office as the operational center.

The Michigan Medicine and U-M Life Sciences Institute proximity matters; Akadeum has had recurring research and development collaborations with Michigan-based academic groups, and the recruiting bench overlaps with the U-M biology and bioengineering pipeline.

Leadership and people

The company's leadership has been built around the founding team and operators with backgrounds across life sciences tools companies. The CEO and founding team have been the public face of the company; specific current titles should be verified on the Akadeum website before citing.

The investor base has included regional and life-sciences-focused investors with experience in tools and reagents commercialization. That investor profile is a tell: tools businesses scale on a different timeline and capital pattern than therapeutics, and the investor bench has been composed accordingly. The 2025 financing round broadened the investor base while keeping the capital efficiency posture intact.

Why it matters

Three reasons Akadeum belongs in the Ann Arbor story.

First, the technology is genuinely novel. BACS is a different physical principle for cell separation than the magnetic and flow-based methods that have dominated for decades. Genuinely novel platform technologies are rare in life sciences tools, and the ones that work tend to compound into long-cycle businesses.

Second, the cell-based therapy timing is favorable. The growing pipeline of CAR-T cell therapies, regenerative medicine cell therapies, and other cell-based therapeutics has created a sustained demand environment for cell separation technologies that scale gently and cleanly. BACS sits squarely inside that demand environment.

Third, Akadeum is one of the cleanest examples of a technically novel Ann Arbor medtech company that has scaled commercially without the visibility of a clinical-stage biopharma like HistoSonics or Strata Oncology. The Ann Arbor medtech bench needs more companies like this; tools businesses are durable, they hire across multiple disciplines, and they anchor the broader life sciences cluster in the city.

Related

• Strata Oncology is the Ann Arbor precision oncology network that overlaps with Akadeum on translational research customers.
• ONL Therapeutics is the Ann Arbor U-M-spinout clinical-stage biopharma working in ocular neuroprotection.
• Ripple Science is the Ann Arbor clinical trial recruitment SaaS that intersects with Akadeum's clinical translational customer base.
• The medtech category hub covers the broader Ann Arbor medtech bench.
• The companies directory is the master index.

FAQ

Where is Akadeum Life Sciences headquartered? Akadeum Life Sciences is headquartered in Ann Arbor, Michigan.

When was Akadeum founded? 2014. The company was founded to commercialize buoyancy-activated cell sorting (BACS), a microbubble-based cell separation technology.

What does Akadeum do? Akadeum builds cell separation products based on its proprietary buoyancy-activated cell sorting (BACS) technology. The product line includes reagents for specific cell separation applications and the Alerion automated cell separation system, launched in 2023.

How does BACS differ from MACS or FACS? MACS uses magnetic beads attached to antibodies to pull cells out of suspension. FACS uses flow cytometry to gate cells one at a time under high-pressure optics. BACS uses gas-filled microbubbles attached to antibodies; the bubble-cell complexes float to the top of the sample tube and are separated by gravity. The result is faster, gentler, and more scalable than MACS or FACS for many applications.

How much funding has Akadeum raised? Akadeum closed a $20M+ financing in June 2025, on top of earlier rounds. Total funding is meaningful but the company has been deliberate about capital efficiency.

Who are Akadeum's customers? The customer base spans academic and government research labs, biopharma R&D, and translational and clinical labs. Cell-based therapy developers (CAR-T, regenerative medicine) are an increasingly important customer segment.

Is Akadeum hiring? Yes. Open roles in research and development, manufacturing, quality, product, field application science, and commercial functions are posted at akadeum.com/careers. Most lab and manufacturing roles are on-site in Ann Arbor, with hybrid flexibility for commercial and non-bench roles.

Who are Akadeum's investors? The disclosed investor list includes Arboretum Ventures, Baird Capital, Plymouth Growth, Beringea, Michigan Angel Fund, and Invest Michigan, with participation from additional strategic and regional investors across multiple rounds.

Strategic reading

Life-sciences tools is a distinctive business model inside the broader life-sciences economy. Unlike therapeutics, tools companies do not need FDA approval for product launch in most research applications. Unlike diagnostics, they do not need reimbursement coding. The economics are recurring consumables and instrument sales into a customer base that is generally stable (academic research labs, biopharma R&D, translational groups), and the durability of successful tools businesses is part of why companies such as Thermo Fisher, Danaher, and Merck KGaA have historically been aggressive acquirers in the category.

Akadeum's position in the cell-separation sub-market is defensible on multiple fronts. The underlying microbubble physics and surface chemistry are protected by patents and continuing R&D investment. The application breadth is expanding as the company validates new cell types and protocols. The Alerion system extends the business from consumables into instruments, which is the classic life-sciences tools playbook for deepening customer relationships and increasing revenue per account. The growing cell and gene therapy manufacturing market is a powerful tailwind: every commercial cell therapy requires scalable, gentle, and regulated cell-separation steps at one or more points in its workflow.

Risks worth naming. Competitive alternatives to BACS include established MACS (Miltenyi Biotec is the dominant supplier) and FACS (BD Biosciences is the dominant instrument vendor), both of which have massive incumbent customer bases. New cell-separation approaches from other startups could further fragment the category. Regulatory requirements for cell-therapy manufacturing continue to evolve, and Alerion's compliance footprint will need to keep pace. None of those risks are fatal to the thesis; all of them are the reasons Akadeum continues to invest in R&D and regulatory alignment as core competitive moats.